SCHEMBL8536887

SCHEMBL8536887

CCSc1ccccc1-c1cc(/C=C2\SC(=S)NC2=O)cc(C)c1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.61
GAA P10253 2/20 0.61
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
ALDH1A1 P00352 1/20 0.61
LMNA P02545 1/20 0.61
POLB P06746 1/20 0.61
MAPT P10636 1/20 0.61
NAT1 P18440 7/20 0.50
CISD1 Q9NZ45 1/20 0.47
PTGS2 P35354 1/20 0.47
CA2 P00918 1/20 0.46
EPHX1 P07099 1/20 0.46
PIM1 P11309 2/20 0.45
DYRK1A Q13627 1/20 0.45
PIM3 Q86V86 1/20 0.45
DYRK2 Q92630 1/20 0.45
PIM2 Q9P1W9 1/20 0.45
MYC P01106 2/20 0.45
MAX P61244 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8307815 0.79 DYRK1A (0.61) NPC1GAAMEN1KMT2AALDH1A1
SCHEMBL8307819 0.79 DYRK1A (0.61) NPC1GAAMEN1KMT2AALDH1A1
SCHEMBL20006065 0.79 NPC1 (0.80) NPC1GAAMEN1KMT2AALDH1A1
SCHEMBL8310306 0.78 MEN1 (1.00) NPC1GAAMEN1KMT2AALDH1A1
SCHEMBL8308378 0.78 MEN1 (1.00) NPC1GAAMEN1KMT2AALDH1A1
SCHEMBL8306587 0.77 PTGS2 (0.69) NPC1GAAMEN1KMT2AALDH1A1
SCHEMBL8306585 0.77 PTGS2 (0.69) NPC1GAAMEN1KMT2AALDH1A1
SCHEMBL27421195 0.72 DYRK1A (0.60) NPC1GAAMEN1KMT2AALDH1A1
SCHEMBL8535412 0.71 PTGS2 (0.85) NPC1GAAMEN1KMT2AALDH1A1
SCHEMBL8535410 0.71 PTGS2 (0.85) NPC1GAAMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0434394-B1 Compounds for treating inflammatory bowel disease LILLY CO ELI (US) 1998-08-05 EP disclosed
EP-0722729-A2 Aryl-substituted rhodanines for treating multiple sclerosis ELI LILLY AND COMPANY (US) 1996-07-24 EP disclosed
US-5387690-A Method of treating inflammatory bowel disease ELI LILLY AND COMPANY (US) 1995-02-07 US disclosed
US-5216002-A Using benzyl substituted rhodanine derivatives as pure enantiomeric form ELI LILLY AND COMPANY (US) 1993-06-01 US disclosed
US-5158966-A Aryl-substituted rhodanine derivatives THE UNIVERSITY OF COLORADO FOUNDATION, INC. (US) 1992-10-27 US disclosed
EP-0434394-A2 Compounds for treating inflammatory bowel disease ELI LILLY AND COMPANY (US) 1991-06-26 EP disclosed